MUMBAI and BALTIMORE — Pharma Major Lupin announced that Lupin Pharmaceuticals, its U.S. subsidiary, has launched niacin extended-release tablets USP in 500-mg, 750-mg and 1,000-mg strengths.
The drug is the generic version of AbbVie’s Niaspan tablets. It's used to reduce elevated TC, LDL-C, Apo B and TG levels, and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia, the company said.
“We are happy to launch this product having received approval from the FDA yesterday. The launch bears testimony to our commitment to serving our customers and patients by bringing high quality, affordable medicines to the market," Vinita Gupta, CEO Lupin Limited, said.
Niaspan tablets had annual sales in the U.S. of approximately $1 billion, according to IMS MAT data.